title: Entecavir and lamivudine therapy for severe acute chronic hepatitis B.
abstract: Severe acute exacerbation in patients with chronic hepatitis B is a unique clinical presentation that results in high mortality. To compare the efficacy of 4 weeks of entecavir or lamivudine therapy in patients with severe acute exacerbation caused by chronic hepatitis B, 65 patients were retrospectively analyzed. The groups received 0.5 mg entecavir (group A) or 100 mg lamivudine (group B) daily. After 4 weeks of treatment, virological and biochemical responses and the deterioration rates were determined. The average age and alanine aminotransferase (ALT), bilirubin, albumin, creatinine (Cr), and HBV DNA levels were similar in groups A and B prior to treatment, but the prothrombin time (PT) was shorter in group A. Following treatment, ALT and bilirubin levels were improved while there were no significant changes in PT, albumin or Cr levels at week 4 in group B. Only ALT was markedly upregulated following treatment in group A. There were no significant differences between the virological and biochemical responses or the deterioration rates of the two groups. These results suggested that short-term treatment with lamivudine markedly alleviated the increased bilirubin (TB) levels in patients with severe acute exacerbation of chronic hepatitis B and that there was no significant difference in the deterioration rate between patients treated by the two types of medication.
authors: Department of Gastroenterology, Shandong Provincial Qianfoshan Hospital; Zhejiang University, Zhejiang;
authors: Changhong
authors: C
authors: Liu
authors: Jing
authors: J
authors: Ye
authors: Hongyu
authors: H
authors: Jia
authors: Meijuan
authors: M
authors: Zhang
authors: Hongfeng
authors: H
authors: Han
authors: Fengzhe
authors: F
authors: Chen
authors: Congkang
authors: C
authors: Chen
keywords: entecavir; hepatitis B virus; lamivudine; severe acute exacerbation
references: J Hepatol. 2003 Mar;38(3):322-7
references: 12586298
references: Hepatol Int. 2009 Mar;3(1):269-82
references: 19669378
references: J Antimicrob Chemother. 2007 Aug;60(2):201-5
references: 17556353
references: Aliment Pharmacol Ther. 2001 Nov;15(11):1737-44
references: 11683687
references: N Engl J Med. 2004 Oct 7;351(15):1521-31
references: 15470215
references: J Hepatol. 2011 Feb;54(2):236-42
references: 21030105
references: Antivir Ther. 2008;13(4):571-9
references: 18672536
references: Hepatology. 2009 May;49(5 Suppl):S174-84
references: 19399794
references: Hepatology. 2009 May;49(5):1503-14
references: 19280622
references: Antivir Ther. 2006;11(4):465-71
references: 16856620
references: J Gastroenterol Hepatol. 2005 Mar;20(3):426-32
references: 15740488
references: J Viral Hepat. 2002 Nov;9(6):424-8
references: 12431204
references: N Engl J Med. 1997 Dec 11;337(24):1733-45
references: 9392700
references: Hepatology. 2006 Dec;44(6):1656-65
references: 17133475
references: Gut. 2003 Apr;52(4):614
references: 12631687
references: Z Gastroenterol. 2004 Jan;42(1):15-8
references: 14997399
references: J Gastroenterol Hepatol. 2009 Jul;24(7):1179-86
references: 19682192
references: Intervirology. 2004;47(6):335-41
references: 15564745
references: Hepatol Int. 2008 Sep;2(3):263-83
references: 19669255